The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline/Sierra Oncology; Incyte; Karyopharm Therapeutics; Novartis; PharmaEssentia
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; GlaxoSmithKline/Sierra Oncology; Karyopharm Therapeutics
Research Funding - Astellas Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Disc Medicine (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Kartos Therapeutics (Inst); NS Pharma (Inst); Pfizer (Inst); Promedior (Inst); Telios (Inst)
 
Nico Gagelmann
No Relationships to Disclose
 
Vikas Gupta
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; Novartis; Pfizer; Sierra Oncology; Takeda
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; Novartis; Roche; Sierra Oncology
Research Funding - Novartis (Inst)
 
Donal P. McLornan
Honoraria - Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Abbvie; Bristol-Myers Squibb/Celgene; Jazz Pharmaceuticals; Novartis
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Novartis (Inst)
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; CTI BioPharma Corp; Genentech/Roche; Incyte; MorphoSys; Novartis; Pfizer; Stemline Therapeutics
Speakers' Bureau - Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Haifa Kathrin Al-Ali
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Kartos Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Bristol-Myers Squibb (Inst); German Leukemia and Lymphoma Foundation (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; Novartis
Other Relationship - GlaxoSmithKline/Sierra Oncology
 
Haris Ali
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Incyte
Speakers' Bureau - Incyte
 
Philipp Treskes
Employment - IQVIA
Stock and Other Ownership Interests - CTI BioPharma Corp
Consulting or Advisory Role - CTI BioPharma Corp
 
Sarah Buckley
Employment - CTI BioPharma Corp
Stock and Other Ownership Interests - CTI BioPharma Corp
 
Karisse Roman-Torres
Employment - CTI BioPharma Corp
Stock and Other Ownership Interests - CTI BioPharma Corp
 
Bart L. Scott
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Alexion Pharmaceuticals; Bristol-Myers Squibb; Celgene; Incyte; Jazz Pharmaceuticals; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Other Relationship - Johnson & Johnson; Nektar